Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5873045 | 0.92 | ALDH1A1 (0.41) | TSHRUSP2HPGDNPSR1SLC6A7 | |
| SCHEMBL5873165 | 0.91 | SLC6A7 (0.41) | SLC6A7PIM1MEN1KMT2AALDH1A1 | |
| SCHEMBL5873025 | 0.91 | ALDH1A1 (0.43) | TSHRHPGDNPSR1PIM1MEN1 | |
| SCHEMBL5770403 | 0.91 | PIM1 (0.42) | PIM1MEN1KMT2AALDH1A1HTT | |
| SCHEMBL5872958 | 0.89 | MKNK1 (0.43) | PIM1MEN1KMT2AALDH1A1HTT | |
| SCHEMBL5872913 | 0.88 | DYRK1A (0.40) | PIM1MEN1KMT2AALDH1A1HTT | |
| SCHEMBL5873054 | 0.88 | PIM1 (0.40) | PIM1MEN1KMT2AALDH1A1HTT | |
| SCHEMBL5873133 | 0.88 | TACR3 (0.42) | TSHRMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5873145 | 0.87 | TACR3 (0.40) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL5873094 | 0.86 | ADORA2A (0.37) | PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | TSHR 4305/4885USP2 3101/4885HPGD 378/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | TSHR 4305/4885USP2 3101/4885HPGD 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.